US OptionsDetailed Quotes

LTRN241220P4000

Watchlist
  • 0.00
  • 0.000.00%
15min DelayTrading Dec 3 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

News

Comments

    Trytosaveabit
    Trytosaveabit
    4 hours ago
    News
    $Lantern Pharma (LTRN.US)$ Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
    5 MINUTES AGO, 8:00 AM EST
    VIA BUSINESSWIRE
    Jaguar8
    Jaguar8
    4 hours ago
    NEWS
    $Lantern Pharma (LTRN.US)$
    Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
    Tuesday, 3rd December at 8:00 am
    • This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024.
    • Fast Track Designation for LP-184 recognizes TNBC as a serious condition impacting approximately 29,000 patients annually in th...
    Jaguar8
    Jaguar8
    Nov 26 07:48
    NEWS
    $Lantern Pharma (LTRN.US)$
    Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
    Lantern Pharma and its subsidiary Starlight Therapeutics presented new preclinical data and Phase 1b trial design for LP-184 (STAR-001) in glioblastoma at SNO 2024.
    The data shows LP-184 combined with spironolactone increases GBM cell sensitivity up to 6-fold thro...
    Trytosaveabit
    Trytosaveabit
    Nov 26 07:48
    Update
    $Lantern Pharma (LTRN.US)$ Reuters· 2 mins ago
    Lantern Pharma & Starlight Therapeutics Present LP-184 (Star-001) Phase 1B Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (Sno) 2024 Highlighting Novel Synthetic Lethality
    Trytosaveabit
    Trytosaveabit
    Nov 19 07:00
    Update
    $Lantern Pharma (LTRN.US)$ Lantern Pharma Announces First Patient Dosed in Japan for the Expansion Cohort in the Phase 2 Harmonic™ Clinical Trial of LP-300 in Never-Smoker Nsclc Patients
Read more